Uneek Mehra Insider Profile
4 Followers
Uneek Mehra, Former Officer at BridgeBio Oncology Therapeutics, holds 22.81K shares in BridgeBio Oncology Therapeutics (Ticker: BBOT), holds 0.00 shares in Myovant Sciences (Ticker: MYOV), holds ― shares in 4D Molecular Therapeutics (Ticker: FDMT).
Uneek Mehra BridgeBio Oncology Therapeutics (BBOT)Former Officer
BridgeBio Oncology Therapeutics (BBOT)
Former Officer
Not Ranked
Ranked #93,545 out of 108,921 Corporate Insiders
Uneek Mehra has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Uneek Mehra holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Uneek Mehra
Uneek Mehra's Trading History
BridgeBio Oncology Therapeutics
May 05, 2026
Former Officer
Uninformative Sell
4.73K
$204.80K
Myovant Sciences
Mar 10, 2023
―
Uninformative Sell
―
$0.00
4D Molecular Therapeutics
―
Chief Financial & Business Officer
―
―
List of latest transactions for each holding click on a transaction to see Uneek Mehra's performance on stock
You May Also Like
Uneek Mehra insider profile FAQ
What is the percentage of profitable transactions made by Uneek Mehra?
The percentage of profitable transactions made by Uneek Mehra is ―.
What is the average return per transaction made by Uneek Mehra?
The average return per transaction made by Uneek Mehra is ―.
What stocks does Uneek Mehra hold?
Uneek Mehra holds: BBOT, MYOV, FDMT stocks.
What was Uneek Mehra’s latest transaction?
Uneek Mehra latest transaction was an Uninformative Sell of $4.73K.
What was Uneek Mehra's most profitable transaction?
Uneek Mehra’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Uneek Mehra's role in BridgeBio Oncology Therapeutics?
Uneek Mehra's role in BridgeBio Oncology Therapeutics is Former Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.